RESUMEN
Cancer causes a fifth of deaths in the Caribbean region and its incidence is increasing. Incidence and mortality patterns of cancer in the Caribbean reflect globally widespread epidemiological transitions, and show cancer profiles that are unique to the region. Providing comprehensive and locally responsive cancer care is particularly challenging in the Caribbean because of the geographical spread of the islands, the frequently under-resourced health-care systems, and the absence of a cohesive approach to cancer control. In many Caribbean countries and territories, cancer surveillance systems are poorly developed, advanced disease presentations are commonplace, and access to cancer screening, diagnostics, and treatment is often suboptimal, with many patients with cancer seeking treatment abroad. Capacity building across the cancer-control continuum in the region is urgently needed and can be accomplished through collaborative efforts and increased investment in health care and cancer control.
Asunto(s)
Detección Precoz del Cáncer , Neoplasias/epidemiología , Región del Caribe/epidemiología , Causas de Muerte , Humanos , Turismo Médico , Neoplasias/terapiaAsunto(s)
Infecciones por Coronavirus/epidemiología , Neoplasias/terapia , Neumonía Viral/epidemiología , Bermudas/epidemiología , Betacoronavirus , COVID-19 , Instituciones Oncológicas , Infecciones por Coronavirus/prevención & control , Humanos , Colaboración Intersectorial , Neoplasias/diagnóstico , Pandemias/prevención & control , Manejo de Atención al Paciente , Neumonía Viral/prevención & control , Oncología por Radiación , SARS-CoV-2RESUMEN
PURPOSE: The purpose of this study was to assess the accuracy of a virtual consultation (VC) process in determining treatment strategy for patients with malignant epidural spinal cord compression (MESCC). METHODS AND MATERIALS: A prospective clinical database was maintained for patients with MESCC. A virtual consultation process (involving exchange of key predetermined clinical information and diagnostic imaging) facilitated rapid decision-making between oncologists and spinal surgeons. Diagnostic imaging was reviewed retrospectively (by R.R.) for surgical opinions in all patients. The primary outcome was the accuracy of virtual consultation opinion in predicting the final treatment recommendation. RESULTS: After excluding 20 patients who were referred directly to the spinal surgeon, 125 patients were eligible for virtual consultation. Of the 46 patients who had a VC, surgery was recommended in 28 patients and actually given to 23. A retrospective review revealed that 5/79 patients who did not have a VC would have been considered surgical candidates. The overall accuracy of the virtual consultation process was estimated at 92%. CONCLUSION: The VC process for MESCC patients provides a reliable means of arriving at a multidisciplinary opinion while minimizing patient transfer. This can potentially shorten treatment decision time and enhance clinical outcomes.
Asunto(s)
Toma de Decisiones , Comunicación Interdisciplinaria , Compresión de la Médula Espinal/radioterapia , Compresión de la Médula Espinal/cirugía , Neoplasias de la Columna Vertebral/radioterapia , Neoplasias de la Columna Vertebral/cirugía , Telemedicina/métodos , Adulto , Anciano , Anciano de 80 o más Años , Terapia Combinada , Consenso , Bases de Datos Factuales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Oncología por Radiación/métodos , Radiografía , Derivación y Consulta , Estudios Retrospectivos , Compresión de la Médula Espinal/diagnóstico por imagen , Compresión de la Médula Espinal/etiología , Neoplasias de la Columna Vertebral/diagnóstico por imagen , Neoplasias de la Columna Vertebral/secundarioRESUMEN
The term 'locally advanced breast cancer' covers a range of clinical scenarios, and has the implications that surgical clearance and local control will be difficult or impossible, and long-term survival rates will be poor. Treatment selection is particularly important in this group of patients to try to obtain maximum control of disease, and potentially improve surgical options and cure rates. Currently, assessment of estrogen receptor, progesterone receptor and human epidermal receptor 2 status in tumour samples remains the gold standard for prediction of response to endocrine therapy, chemotherapy or targeted agents such as trastuzumab. Progress has been made in identifying markers that can help select treatments likely to be associated with response and avoid those associated with resistance. These potential markers include Ki67 proliferation rate, cytochrome P450 (CYP) 2D6 expression, BRCA1/2 gene status and others.